Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ADCT – Adc Therapeutics SA

ADCT — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

6.22

Margin Of Safety %

Put/Call OI Ratio

0.05

EPS Next Q Diff

-0.01

EPS Last/This Y

0.27

EPS This/Next Y

0.2

Price

1.05

Target Price

4.75

Analyst Recom

2.14

Performance Q

-74.33

Upside

-3,567.0%

Beta

1.94

Ticker: ADCT




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-05-18ADCT3.160.040.013148
2026-05-19ADCT3.150.042.113612
2026-05-20ADCT3.240.050.103665
2026-05-21ADCT3.420.051.673677
2026-05-22ADCT3.390.050.143694
2026-05-26ADCT3.530.050.003744
2026-05-27ADCT3.440.050.643765
2026-05-28ADCT3.450.060.043829
2026-05-29ADCT3.40.060.003851
2026-06-02ADCT3.170.080.024048
2026-06-03ADCT3.080.070.014259
2026-06-04ADCT1.320.110.224655
2026-06-05ADCT10.070.044872
2026-06-08ADCT0.97760.050.004839
2026-06-09ADCT1.150.051.574898
2026-06-10ADCT1.1050.050.004879
2026-06-11ADCT1.070.055.004878
2026-06-12ADCT1.0550.051.504879
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-05-18ADCT3.16- - -0.85
2026-05-19ADCT3.15- - -0.85
2026-05-20ADCT3.25- - -0.85
2026-05-21ADCT3.42- - -0.85
2026-05-22ADCT3.39- - -0.85
2026-05-26ADCT3.53- - -0.85
2026-05-27ADCT3.44- - -0.85
2026-05-28ADCT3.45- - -0.85
2026-05-29ADCT3.40- - -0.85
2026-06-01ADCT3.40- - -0.85
2026-06-02ADCT3.16- - -0.85
2026-06-03ADCT3.08- - -0.85
2026-06-04ADCT1.32- - -0.85
2026-06-05ADCT1.02- - -0.85
2026-06-08ADCT0.98- - -0.84
2026-06-09ADCT1.11- - -0.84
2026-06-10ADCT1.10- - -0.84
2026-06-11ADCT1.07- - -0.84
2026-06-12ADCT1.05- - -0.85
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-05-18ADCT-14.933.355.84
2026-05-19ADCT-14.943.355.86
2026-05-20ADCT-14.803.355.86
2026-05-21ADCT-14.803.355.59
2026-05-22ADCT-16.693.355.59
2026-05-26ADCT-16.691.525.59
2026-05-27ADCT-16.691.525.59
2026-05-28ADCT-16.691.525.87
2026-05-29ADCT-16.691.525.87
2026-06-02ADCT-16.691.455.87
2026-06-03ADCT-16.691.455.87
2026-06-04ADCT-16.691.455.87
2026-06-05ADCT-16.691.455.87
2026-06-08ADCT-16.691.465.90
2026-06-09ADCT-16.521.465.90
2026-06-10ADCT-16.521.466.22
2026-06-11ADCT-16.521.466.22
2026-06-12ADCT-16.521.466.22
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.21

Avg. EPS Est. Current Quarter

-0.21

Avg. EPS Est. Next Quarter

-0.22

Insider Transactions

-16.52

Institutional Transactions

1.46

Beta

1.94

Average Sales Estimate Current Quarter

19

Average Sales Estimate Next Quarter

19

Fair Value

Quality Score

72

Growth Score

28

Sentiment Score

22

Actual DrawDown %

96.7

Max Drawdown 5-Year %

-98.5

Target Price

4.75

P/E

Forward P/E

PEG

P/S

1.7

P/B

P/Free Cash Flow

EPS

-1.05

Average EPS Est. Cur. Y​

-0.85

EPS Next Y. (Est.)

-0.65

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-173.02

Relative Volume

0.95

Return on Equity vs Sector %

35.7

Return on Equity vs Industry %

52.1

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

ADCT Healthcare
$1.06
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
16/20
Pullback
11/25
Volume
7/15
Valuation
12/20
TP/AR
1/10
Options
6/10
RSI
14.9
Range 1M
9.2%
Sup Dist
2.5%
🚀
Momentum Growth
Ride accelerating trends
N/A
37 /100
WEAK
Momentum
10/25
Growth
14/30
Estimates
2/20
Inst/Vol
4/15
Options
7/10
EPS Yr
23.8%
EPS NY
23.6%
52W%
6.4%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +348.1% upside
Quality
7/30
Valuation
16/30
Growth
14/25
Stability
7/10
LT Trend
3/5
Upside
+348.1%
Quality
72
ADC Therapeutics SA
Sector: Healthcare
Industry: Biotechnology
Employees: 188
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
ADCT

Latest News

Caricamento notizie per ADCT
stock quote shares ADCT – Adc Therapeutics SA Stock Price stock today
news today ADCT – Adc Therapeutics SA stock forecast ,stock prediction 2023 2024 2025
marketwatch ADCT – Adc Therapeutics SA yahoo finance google finance
stock history ADCT – Adc Therapeutics SA invest stock market
stock prices ADCT premarket after hours
ticker ADCT fair value insiders trading